Sunday, Nov. 22, 2026 A Vik Media Group publication
Mongevity Longevity in Motion
Leer en español

Knee osteoarthritis research: approved drug eased joint damage in mice and monkeys

☕ Includes a question for the family ↓

Knee osteoarthritisPart of a story we are following · 4 articles · See every update
An aqua spinning class aboard MSC Divina , a Miami-based cruise ship, in 2013.
An aqua spinning class aboard MSC Divina , a Miami-based cruise ship, in 2013.Photo: Gary Bembridge / Wikimedia Commons, CC BY 2.0

If you live with knee osteoarthritis, here is some encouraging news from the lab. Scientists found that a drug already approved by the FDA eased joint damage and pain in animals with osteoarthritis. It has not been tested in people for this purpose yet.

In a study of mice and cynomolgus macaques (a type of monkey) with osteoarthritis, the drug dabigatran slowed cartilage breakdown, eased pain and improved how the joints worked. Researchers also found how it does this, and that opens a new path for treating the condition.

How the study worked

Researchers first screened a library of FDA-approved drugs to find one that could calm two of the main inflammation signals behind osteoarthritis, called TNF-α and IL-1β. They then tested the winner, dabigatran, in cartilage cells and in mouse and monkey models of the disease, and published the work in Science Translational Medicine on November 11, 2026. This was preclinical research, so the results come from cells and animals, and the next step is testing in people.

What they found

Osteoarthritis is a leading cause of disability. Inside the joint, the cartilage cells are under constant, low-level inflammation, and their energy use goes off track. Two inflammation signals, TNF-α and IL-1β, are major drivers of that process.

Drugs aimed at just one of those signals have not worked in clinical trials. That led scientists to think a drug that hits both at once might do better. Dabigatran turned out to do exactly that. In the lab, it calmed both signals and restored the metabolism of cartilage cells.

In mice and in cynomolgus macaques, the results were clear:

  • Cartilage breakdown slowed.
  • Pain eased.
  • Joint function improved.

The fact that the benefit showed up in monkeys as well as mice matters. Monkeys are much closer to us than mice, so results in them are a stronger sign.

How does the drug work?

Think of a cell as a house with mailboxes on the outside. TNF-α and IL-1β are messages that drop into those mailboxes and tell the cell to cause inflammation. The mailboxes are called receptors.

The team found that dabigatran attaches to a protein called BIG2, which no one knew it could bind. BIG2 helps move receptors around the cell. With dabigatran attached, two things happen:

  • The receptor for TNF-α is released from the cell surface, so that message has fewer places to land.
  • The receptor for IL-1β is sent to the cell’s recycling system, where it is broken down, so that message cannot get in either.

With both mailboxes dealt with, the inflammation signals fade. This is why scientists now see BIG2 and receptor traffic as a new target for osteoarthritis treatment.

What you can do today

Nothing about your care changes today. Dabigatran has not been tested for arthritis in people, so it is not a treatment for osteoarthritis, and you should not take it for that purpose. What you can do is get ready for your next appointment. Spend a few minutes writing down which activities make your joints ache and which ones feel better. That note gives your care team a clear picture of what is going on.

For clinicians and researchers

Design: Preclinical study in mice and cynomolgus macaques with osteoarthritis models, plus a screen of an FDA-approved drug library and biochemical copurification with mass spectrometry to identify the target. Sample sizes and follow-up are not given in the abstract.

Main result: Dabigatran, a thrombin inhibitor, suppressed TNF-α and IL-1β signaling, attenuated cartilage degeneration, alleviated pain and improved joint function in both species. It binds BIG2, which dampens TNF-α signaling via TNFR1 release and limits IL-1β effects via IL-1R1 degradation.

Main limitation: Animal models and cell-based mechanistic work only; no human data, and the abstract reports no sample sizes, effect sizes or follow-up, so benefit in human OA cannot be inferred.

How it fits: Earlier Mongevity articles covered arthritis in pets (cats), using different approaches; this study addresses osteoarthritis with a repurposed drug in mice and primates, extending preclinical work on joint disease. A shot every three months helps cats move better, a win for arthritis in pets · New hope for arthritis in pets: cats moved better after donor cell infusions

Open question: Whether dabigatran or BIG2-targeted approaches benefit people with osteoarthritis remains untested; clinical trials would be needed, along with evaluation of safety given dabigatran’s anticoagulant action.

Talk about it at home

Think of every cell in a joint as a little house with mailboxes outside, where messages can drop in telling the cell to get inflamed. Scientists searched for a helper that could keep those messages from getting in, and they found a substance that moves the mailboxes out of the way so fewer messages can land. They tried it in cells, in mice and in monkeys, and the joints of the animals worked better, so now they want to find out whether it could help people too.

Question for the table

Ask a grandparent or another older person how they sent messages to their friends when they were young, long before phones in every pocket. What did they do when they wanted to say something quickly, and how long did they wait for an answer?

Keep exploring

Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.

Got a question? Ask us ›

Get the best of longevity science by emailThe most useful new studies, in plain language and with the source. Free.

We'll email you once to confirm. Occasional messages from our sponsors, clearly labeled. Unsubscribe anytime. We never ask for health data.
Cite this article
AMA
Mongevity Desk. Knee osteoarthritis research: approved drug eased joint damage in mice and monkeys. Mongevity. Published November 21, 2026. Accessed November 22, 2026. https://mongevity.science/muscle-and-bone/2026/11/knee-osteoarthritis-approved-drug-eased-joint-damage-mice-monkeys/
Vancouver
Mongevity Desk. Knee osteoarthritis research: approved drug eased joint damage in mice and monkeys [Internet]. Mongevity; 2026 Nov 21 cited 2026 Nov 22]. Available from: https://mongevity.science/muscle-and-bone/2026/11/knee-osteoarthritis-approved-drug-eased-joint-damage-mice-monkeys/
APA
Mongevity Desk. (2026, November 21). Knee osteoarthritis research: approved drug eased joint damage in mice and monkeys. Mongevity. https://mongevity.science/muscle-and-bone/2026/11/knee-osteoarthritis-approved-drug-eased-joint-damage-mice-monkeys/
For your website
<a href="https://mongevity.science/muscle-and-bone/2026/11/knee-osteoarthritis-approved-drug-eased-joint-damage-mice-monkeys/">Knee osteoarthritis research: approved drug eased joint damage in mice and monkeys</a>

Free to share or quote with credit and a link.

Questions and answers

Can I take dabigatran for osteoarthritis now?
No. It has only been tested for osteoarthritis in mice and monkeys. Current advice for people does not change.
Which animals were studied?
Mice and cynomolgus macaques, a type of monkey, both with osteoarthritis.
What did the drug do in the animals?
It slowed cartilage breakdown, eased pain and improved joint function.
Why does a drug that is already approved matter?
The researchers found it by screening FDA-approved drugs, and it works through a newly discovered target called BIG2, which gives scientists a fresh path for osteoarthritis treatment.

Sources

  1. Sci Transl Med: Dual inhibition of TNF-α and IL-1β signaling through BIG2 ameliorates osteoarthritis in mouse and primate models (PMID 43013683 · DOI 10.1126/scitranslmed.aec8494) · 2026-11-22

More on this story

Report an error